10-QPeriod: Q2 FY2014

QUEST DIAGNOSTICS INC Quarterly Report for Q2 Ended Jun 30, 2014

Filed July 31, 2014For Securities:DGX

Summary

Quest Diagnostics reported a decrease in net income attributable to stockholders for the second quarter of 2014, falling to $133 million from $165 million in the prior year period. This was accompanied by a decline in diluted earnings per share from continuing operations to $0.92 from $0.99. The company experienced revenue growth, with total net revenues increasing by 4.8% to $1.9 billion, largely driven by a 5.3% rise in Diagnostic Information Services (DIS) revenue, boosted by recent acquisitions which contributed approximately 7% to DIS revenue growth. However, cost of services rose by 7.3%, outpacing revenue growth, and SG&A expenses also increased, impacting operating income, which declined by 9.2%. Significant strategic investments were made through acquisitions, including Solstas Lab Partners Group, Summit Health, Inc., and Steward Health Care Systems, LLC, which are expected to contribute to future growth but also incurred integration costs. The company continues to execute its 'Invigorate' cost-reduction program, aiming for significant run-rate savings. While this program is helping to offset cost pressures, the overall financial performance in the quarter was impacted by integration and restructuring costs, as well as legal settlement expenses. Despite the sequential improvement in underlying DIS volume compared to Q1 2014, the year-over-year decline indicates ongoing market pressures. Investors should monitor the integration success of recent acquisitions and the effectiveness of the Invigorate program in driving improved profitability and offsetting the impact of reimbursement pressures.

Financial Highlights

57 data points
Beta

Revenue

$1.90B

38.3% Gross Margin

Net Income

$133.00M

7.0% Net Margin

EPS (Diluted)

$0.92

Total Assets

$9.76B

Cash & Equivalents

$144.00M

Free Cash Flow

$231.00M

Financial Statements
Beta
Revenue$1.90B
Cost of Revenue$1.17B
Gross Profit$728.00M
SG&A Expenses$440.00M
Operating Expenses$1.64B
Operating Income$262.00M
Interest Expense$42.00M
Net Income$133.00M
EPS (Basic)$0.92
EPS (Diluted)$0.92
Shares Outstanding (Basic)144.00M
Shares Outstanding (Diluted)145.00M

Key Highlights

  • 1Total net revenues increased by 4.8% to $1.9 billion, driven by a 5.3% increase in DIS revenue.
  • 2Acquisitions of Solstas Lab Partners Group, Summit Health, and Steward Health Care Systems contributed significantly to DIS revenue and volume growth.
  • 3Net income attributable to Quest Diagnostics stockholders decreased to $133 million from $165 million year-over-year.
  • 4Diluted earnings per share from continuing operations declined to $0.92 from $0.99.
  • 5Cost of services increased by 7.3%, outpacing revenue growth, primarily due to acquisition-related costs and facility cost allocation changes.
  • 6The company continued its 'Invigorate' cost-reduction program, aiming for $700 million in run-rate savings by the end of 2014.
  • 7Significant integration and restructuring costs, as well as legal settlement expenses, impacted profitability during the period.

Frequently Asked Questions

Revenue growth was primarily driven by the Diagnostic Information Services (DIS) segment, which saw a 5.3% increase. This growth was significantly boosted by recent acquisitions, including Solstas Lab Partners Group, Summit Health, and Steward Health Care Systems, which collectively added approximately 7% to DIS revenue growth.

Despite revenue growth, net income and earnings per share declined due to several factors. These included a substantial increase in the cost of services (up 7.3%) driven by acquisition-related operating costs and changes in facility cost allocation. Selling, general, and administrative expenses also increased. Additionally, the company incurred significant integration and restructuring costs related to its acquisitions and the ongoing 'Invigorate' program, as well as costs associated with legal settlements.

The 'Invigorate' program is a multi-year initiative designed to reduce Quest Diagnostics' cost structure, aiming for $700 million in run-rate savings by the end of 2014. It aims to offset reimbursement pressures, reduce labor and benefit costs, and free up resources for investment in science and innovation. While it helps manage costs, the program also involves restructuring initiatives that have led to recorded charges.

The acquisitions of Solstas, Summit Health, and Steward are contributing to DIS revenue and volume growth. However, they also resulted in increased operating costs, integration and transaction expenses, and amortization of acquired intangible assets, which have negatively impacted short-term profitability. The company is working to realize anticipated synergies from these acquisitions.